US EditionA New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
- HistoIndex has launched FibroSIGHT, its first Laboratory Developed Test , now available in the United States for patients with Metabolic Dysfunction-Associated Steatohepatitis .
- FibroSIGHT aims to provide clinicians with a more accurate assessment of liver fibrosis, enhancing clinical decisions and patient care.
- The launch of FibroSIGHT marks a pivotal moment in clinical care for MASH patients, especially after the approval of the first drug for treating MASH with fibrosis.
- Dr. Gideon Ho, CEO of HistoIndex, expressed excitement about improving personalized patient care through more accurate evaluations provided by FibroSIGHT.
Insights by Ground AI
Does this summary seem wrong?
73 Articles
73 Articles
All
Left
3
Center
19
Right
7
The Berkshire Eagle+72 Reposted by 72 other sources
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
SINGAPORE, March 17, 2025 /PRNewswire/ -- HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now available in the United States. This marks…
Coverage Details
Total News Sources73
Leaning Left3Leaning Right7Center19Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
C 66%
R 24%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
